Bristol-Myers Squibb Company Cash Flow Conversion Efficiency
Bristol-Myers Squibb Company cash flow conversion efficiency. Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has a cash flow conversion efficiency ratio of 0.152x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.39 Billion) by net assets ($22.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bristol-Myers Squibb Company (1989–2025)
Cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2025. This chart illustrates how Bristol-Myers Squibb Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BMY share price today for real-time trading data and today's change.
Bristol-Myers Squibb Company Cash Flow Conversion Ratio Explained
Bristol-Myers Squibb Company cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bristol-Myers Squibb Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bristol-Myers Squibb Company ranked by their cash flow conversion efficiency. Also see BMY market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
0.053x |
|
Deutsche Telekom AG
F:DTEA
|
0.115x |
|
Capital One Financial Corporation
NYSE:COF
|
0.074x |
|
Siemens Energy AG
XETRA:ENR
|
0.218x |
|
Siemens Energy AG
F:ENR
|
0.272x |
|
ABB Ltd
SW:ABBN
|
0.117x |
|
FAST RETAIL.CO.SP.HDR 1
F:FR7H
|
0.073x |
|
SCHNEIDER ELECTR.ADR/1/5
F:SNDB
|
N/A |
Annual Cash Flow Conversion Efficiency for Bristol-Myers Squibb Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2025. Review Bristol-Myers Squibb Company (BMY) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.51 Billion | $14.16 Billion | 0.765x | -17.47% |
| 2024-12-31 | $16.39 Billion | $15.19 Billion | 0.927x | +97.18% |
| 2023-12-31 | $29.48 Billion | $13.86 Billion | 0.470x | +11.95% |
| 2022-12-31 | $31.12 Billion | $13.07 Billion | 0.420x | -6.72% |
| 2021-12-31 | $36.01 Billion | $16.21 Billion | 0.450x | +21.35% |
| 2020-12-31 | $37.88 Billion | $14.05 Billion | 0.371x | +137.72% |
| 2019-12-31 | $51.70 Billion | $8.07 Billion | 0.156x | -68.80% |
| 2018-12-31 | $14.13 Billion | $7.07 Billion | 0.500x | +12.33% |
| 2017-12-31 | $11.85 Billion | $5.28 Billion | 0.445x | +138.02% |
| 2016-12-31 | $16.35 Billion | $3.06 Billion | 0.187x | +28.18% |
| 2015-12-31 | $14.42 Billion | $2.10 Billion | 0.146x | -30.54% |
| 2014-12-31 | $14.98 Billion | $3.15 Billion | 0.210x | -9.70% |
| 2013-12-31 | $15.24 Billion | $3.54 Billion | 0.233x | -54.28% |
| 2012-12-31 | $13.64 Billion | $6.94 Billion | 0.509x | +66.85% |
| 2011-12-31 | $15.87 Billion | $4.84 Billion | 0.305x | +6.22% |
| 2010-12-31 | $15.64 Billion | $4.49 Billion | 0.287x | +4.45% |
| 2009-12-31 | $14.79 Billion | $4.07 Billion | 0.275x | -9.46% |
| 2008-12-31 | $12.21 Billion | $3.71 Billion | 0.304x | +1.72% |
| 2007-12-31 | $10.56 Billion | $3.15 Billion | 0.299x | +43.18% |
| 2006-12-31 | $9.99 Billion | $2.08 Billion | 0.208x | +27.27% |
| 2005-12-31 | $11.21 Billion | $1.84 Billion | 0.164x | -47.38% |
| 2004-12-31 | $10.20 Billion | $3.18 Billion | 0.311x | -13.25% |
| 2003-12-31 | $9.79 Billion | $3.51 Billion | 0.359x | +232.52% |
| 2002-12-31 | $8.76 Billion | $945.00 Million | 0.108x | -78.55% |
| 2001-12-31 | $10.74 Billion | $5.40 Billion | 0.503x | -0.71% |
| 2000-12-31 | $9.18 Billion | $4.65 Billion | 0.507x | +3.71% |
| 1999-12-31 | $8.64 Billion | $4.22 Billion | 0.489x | -2.12% |
| 1998-12-31 | $7.58 Billion | $3.78 Billion | 0.499x | +45.55% |
| 1997-12-31 | $7.22 Billion | $2.48 Billion | 0.343x | -14.68% |
| 1996-12-31 | $6.57 Billion | $2.64 Billion | 0.402x | -6.35% |
| 1995-12-31 | $5.82 Billion | $2.50 Billion | 0.429x | +6.40% |
| 1994-12-31 | $5.70 Billion | $2.30 Billion | 0.403x | -7.12% |
| 1993-12-31 | $5.94 Billion | $2.58 Billion | 0.434x | +28.93% |
| 1992-12-31 | $6.02 Billion | $2.03 Billion | 0.337x | +6.39% |
| 1991-12-31 | $5.79 Billion | $1.83 Billion | 0.317x | -2.08% |
| 1990-12-31 | $5.42 Billion | $1.75 Billion | 0.323x | +38.15% |
| 1989-12-31 | $5.08 Billion | $1.19 Billion | 0.234x | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rhe… Read more